Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Granulocytes & T-cells as biomarkers for relapse in CML following discontinuation of TKIs

David Ross • 8 Sep 2023
SOHO 2023
Chronic Myeloid Leukemia Leukemia

David Ross, MBBS, PhD, FRACP, FRCPA, Royal Adelaide Hospital and Institute, Adelaide, Australia, discusses the identification of granulocytes and T-cells as biomarkers for disease relapse and response prediction following discontinuation of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from David Ross

2:51
The genetic complexity of CML beyond BCR-ABL1 & the clinical impact of additional abnormalities
David Ross • 8 Sep 2023
2:05
ADORE: novel combinations with ruxolitinib for myelofibrosis
David Ross • 1 Jun 2021
1:47
Bomedemstat normalizes platelet count for essential thrombocythemia
David Ross • 1 Jun 2021
1:32
QoL for patients with polycythemia vera or essential thrombocythemia
David Ross • 1 Jun 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals